Any way you look at it, $700 million is a lot of cash. That’s the amount that industries regulated by the FDA have spent since 2009 lobbying Congress and the Executive Branch. That investment is paying off as Congress now considers must-pass legislation that governs how the FDA uses science to evaluate prescription drugs and medical devices. Read More
March 23rd, 2012
As I’m sure you’ve noticed, we have been blogging quite a bit recently about the FDA. This corresponds to legislation that would determine how the FDA approves and monitors drugs and medical devices. But why have we been so focused on reducing the number of FDA advisory panel members who have financial conflicts-of-interest? Read More
March 19th, 2012
In a previous blog post, I explained the FDA’s complex process for approving drugs and medical devices. However, in many cases, pressure from commercial interests has broken down this process. The approval and subsequent recall of Vioxx took its toll on thousands of Americans, including my own father.
March 16th, 2012
March 13th, 2012
When UCS started looking at the use of science at the FDA several years ago, I sat down and read The Jungle, which has been credited with prompting President Theodore Roosevelt to establish the first iteration of the Food and Drug Administration more than a century ago. The grisly descriptions of the Chicago meat-packing industry still conjure up vivid images in my mind.
We’ve made great strides over the past century in protecting the public from unsafe food products. But it’s an entirely different part of the FDA’s wheelhouse that will be taking center stage over the next two months: the regulation of prescription drugs and medical devices. Read More
February 29th, 2012
February brought two significant pieces of good news at the EPA. The agency released its final scientific integrity policy, which was much improved over the draft it put out for public comment. And the EPA finally released a scientific assessment of dioxin, an achievement 27 years in the making. Read More
January 26th, 2012
In August 2011, the Environmental Protection Agency committed to releasing a scientific assessment of the health hazards of chemical dioxins by the end of January 2012. The assessment process has dragged on for nearly three decades—and consistent with what has now become a pattern, the industries that are most responsible for dioxin releases are pushing for yet another delay. Read More